Tenaya Therapeutics, Inc. (TNYA)

2.6950 -0.1600 (-5.60%) 市場開市。 截至 10:39AM EDT。

Tenaya Therapeutics, Inc.

171 Oyster Point Boulevard
Suite 500
South San Francisco, CA 94080
United States
650 825 6990
https://www.tenayatherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 140

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Faraz Ali M.B.A.	CEO & Director	890.06k	無	1973
Dr. Deepak Srivastava M.D.	Scientific Founder, Chairman of Scientific Advisory Board & Director	120.5k	無	1967
Ms. Leone D. Patterson M.B.A.	Chief Financial & Business Officer	619.38k	無	1962
Dr. Whittemore G. Tingley M.D., PH.D.	Chief Medical Officer	645.79k	無	1968
Dr. Eric N. Olson Ph.D.	Scientific Founder & Member of Scientific Advisory Board	無	無	無
Dr. Bruce R. Conklin	Scientific Founder	無	無	無
Dr. Saptarsi Haldar M.D.	Scientific Founder	無	無	無
Dr. Sheng Ding Ph.D.	Scientific Founder	無	無	無
Dr. Benoit G. Bruneau Ph.D.	Scientific Founder	無	無	無
Dr. Kee-Hong Kim Ph.D.	Chief Technology Officer	無	無	1966

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

公司管治

截至 2024年6月1日 止，Tenaya Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：6；董事會：8；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。